Francesca Alessandrini
Research Subjects
Francesca Alessandrini has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Heidrun Behrendt
4 shared publicationsJohannes Ring
Division of Environmental Dermatology and Allergy, GSF National Research Center for Environment and Health/Technical University Munich, Neuherberg, Germany
3 shared publicationsThilo Jakob
2 shared publicationsA. Ziesenis
Institute for Inhalation Biology, GSF Research Center for Environment and Health, Neuherberg, Germany
1 shared publicationAlexander Wolf
1 shared publicationBernd Lentner
1 shared publication
Latest Publications
- 1 April 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 117 (4) , 824-830
Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung
- 1 April 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 117 (4) , 824-830
Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung
- 1 December 2004
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 123 (6) , 1030-1036
Alterations of Glucosylceramide-β-Glucosidase Levels in the Skin of Patients with Psoriasis Vulgaris
- 1 December 2004
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 123 (6) , 1030-1036
Alterations of Glucosylceramide-β-Glucosidase Levels in the Skin of Patients with Psoriasis Vulgaris
- 1 January 2003
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 15 (4) , 343-356
Effects of Inhaled CdO Particles on the Sphingolipid Synthesis of Rat Lungs
Surfactant lipids of the alveolar space protect the lung from various environmental stimuli. We investigated the influence of ultrafine (UF) CdO particles inhalation on two key enzymes involved in lung sphingolipid metabolism, serine palmitoyltransferase (SPT), and sphingomyelinase (SMase). Rats inhaled either 0.63 mg UF-CdO/m 3 for 6 h (group 1), or 1.08 mg UF-CdO/m 3 12 h/day for 10 days (group 2). Two corresponding control groups inhaled filtered clean air. Additional rats intratracheally instilled with lipopolysaccharide (LPS) were used as positive controls. Semiquantitative reverse-transcription polymerase chain reaction (RT-PCR) of lung tissue showed a significant increase in the level of SPT mRNA (LCB2 subunit) expression in group 2 compared to the corresponding controls (p < .01). Group 1 and LPS were not statistically different from control. No alteration in the mRNA level of SMase was detected in any exposure group. The immunohistochemical analysis showed that SPT (LCB2 subunit) localization was stronger in the alveolar type II cells of group 2 lungs compared to the corresponding controls. These results were correlated with alterations in BALF cellular and biochemical parameters and lung morphology. Since SPT is the key enzyme for de novo sphingolipid synthesis in lung surfactant and SMase is responsible for sphingomyelin catabolism, we can postulate that high-dose UF-CdO exposure for 10 days induces an increase in sphingolipid synthesis in the type II cells of rat lungs that would not be promptly followed by its degradation.
- 1 January 2003
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 15 (4) , 343-356
Effects of Inhaled CdO Particles on the Sphingolipid Synthesis of Rat Lungs
Surfactant lipids of the alveolar space protect the lung from various environmental stimuli. We investigated the influence of ultrafine (UF) CdO particles inhalation on two key enzymes involved in lung sphingolipid metabolism, serine palmitoyltransferase (SPT), and sphingomyelinase (SMase). Rats inhaled either 0.63 mg UF-CdO/m 3 for 6 h (group 1), or 1.08 mg UF-CdO/m 3 12 h/day for 10 days (group 2). Two corresponding control groups inhaled filtered clean air. Additional rats intratracheally instilled with lipopolysaccharide (LPS) were used as positive controls. Semiquantitative reverse-transcription polymerase chain reaction (RT-PCR) of lung tissue showed a significant increase in the level of SPT mRNA (LCB2 subunit) expression in group 2 compared to the corresponding controls (p < .01). Group 1 and LPS were not statistically different from control. No alteration in the mRNA level of SMase was detected in any exposure group. The immunohistochemical analysis showed that SPT (LCB2 subunit) localization was stronger in the alveolar type II cells of group 2 lungs compared to the corresponding controls. These results were correlated with alterations in BALF cellular and biochemical parameters and lung morphology. Since SPT is the key enzyme for de novo sphingolipid synthesis in lung surfactant and SMase is responsible for sphingomyelin catabolism, we can postulate that high-dose UF-CdO exposure for 10 days induces an increase in sphingolipid synthesis in the type II cells of rat lungs that would not be promptly followed by its degradation.
- 1 March 2001
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 124 (1-3) , 25-28
ENU Mouse Mutagenesis: Generation of Mouse Mutants with Aberrant Plasma IgE Levels
Background: The ENU Mouse Mutagenesis Project aims at a large-scale, systematic production of mouse mutants using the alkylating agent ethyl-nitrosourea (ENU). Offspring of mutagenized mice are subjected to a multiparameter screen to detect alterations in various phenotypes with the ultimate goal of identifying novel genes relevant for the expression of the phenotype. Using this approach, we have analyzed plasma IgE concentrations to identify mouse mutants with aberrant plasma IgE levels. Methods and Results: ENU-mutagenized male C3HeB/FeJ were mated to wild-type females to produce F1 offspring. F1 animals were analyzed for alterations in their plasma IgE concentrations that showed a dominant mode of inheritance, or bred further to screen for recessive phenotypes. Plasma IgE concentrations were determined by ELISA and a normal range for plasma IgE was established using C3HeB/FeJ wild-type animals. So far we have tested 6568 F1 animals. Repeated testing confirmed a stable aberrant IgE phenotype in 124 animals. To confirm the genetic basis of the observed phenotype, these mice were subjected to confirmation crossing. Currently we have established 9 independent mutant mouse lines (3 with high plasma IgE and 6 with plasma IgE below detection limit) that have been genetically confirmed and additional 24 variant mouse lines are currently undergoing confirmation testing. Conclusion: ENU mouse mutagenesis allowed us to generate and identify mouse mutants with aberrant plasma IgE levels, which may be used to characterize novel genes involved in IgE regulation and may serve as animal models for IgE-mediated diseases.
- 1 March 2001
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 124 (1-3) , 25-28
ENU Mouse Mutagenesis: Generation of Mouse Mutants with Aberrant Plasma IgE Levels
Background: The ENU Mouse Mutagenesis Project aims at a large-scale, systematic production of mouse mutants using the alkylating agent ethyl-nitrosourea (ENU). Offspring of mutagenized mice are subjected to a multiparameter screen to detect alterations in various phenotypes with the ultimate goal of identifying novel genes relevant for the expression of the phenotype. Using this approach, we have analyzed plasma IgE concentrations to identify mouse mutants with aberrant plasma IgE levels. Methods and Results: ENU-mutagenized male C3HeB/FeJ were mated to wild-type females to produce F1 offspring. F1 animals were analyzed for alterations in their plasma IgE concentrations that showed a dominant mode of inheritance, or bred further to screen for recessive phenotypes. Plasma IgE concentrations were determined by ELISA and a normal range for plasma IgE was established using C3HeB/FeJ wild-type animals. So far we have tested 6568 F1 animals. Repeated testing confirmed a stable aberrant IgE phenotype in 124 animals. To confirm the genetic basis of the observed phenotype, these mice were subjected to confirmation crossing. Currently we have established 9 independent mutant mouse lines (3 with high plasma IgE and 6 with plasma IgE below detection limit) that have been genetically confirmed and additional 24 variant mouse lines are currently undergoing confirmation testing. Conclusion: ENU mouse mutagenesis allowed us to generate and identify mouse mutants with aberrant plasma IgE levels, which may be used to characterize novel genes involved in IgE regulation and may serve as animal models for IgE-mediated diseases.
- 1 March 2001
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 116 (3) , 394-400
The Level of Prosaposin is Decreased in the Skin of Patients with Psoriasis Vulgaris
- 1 March 2001
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 116 (3) , 394-400
The Level of Prosaposin is Decreased in the Skin of Patients with Psoriasis Vulgaris